Reuters news agency revealed on Wednesday that the European Commission has decided not to renew COVID-19 vaccine contracts next year with companies such as Astrazeneca and Johnson & Johnson (J&J), according to a report from Italian daily La Stampa which cited a source from the Italian Health Ministry.
La Stampa disclosed that in agreement with the leaders of several (EU) countries, the EU Commission has decided that the contracts with the companies that produce (viral vector) vaccines that are valid for the current year will not be renewed on expiry.
Reportedly, Brussels would rather focus on COVID-19 vaccines from companies such as Pfizer and Moderna that use messenger RNA (mRNA) technology.
In addition, Reuters said the EC is seeking clarification from J&J about the company's "completely unexpected" announcement of delays in COVID-19 vaccine deliveries to the EU.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT